Bioxytran(OTC) BIXT

Bioxytran develops drugs for people with low oxygen in their tissues. Its main products aim to help stroke patients and those with COVID-19. The company focuses on making treatments that improve oxygen delivery and block certain proteins linked to disease.

Lab Bench to Bedside: Products and Services

• BXT-25 (Oxygen Carrier): An injectable drug designed to deliver oxygen to the brain and wounds for people with low tissue oxygen. (0% of revenue; no commercial sales)
• ProLectin-Rx (COVID-19 Therapy): A pectin-based compound that blocks galectin-1, a protein involved in viral infections, targeting mild to moderate COVID-19. (0% of revenue; no commercial sales)
• Pharmalectin, Inc.: Subsidiary focused on developing drugs for viral diseases. (0% of revenue)
• NDPD Pharma, Inc.: Designs manufacturing equipment and carbohydrate-based drug prototypes. (0% of revenue)
• Pharmalectin BVI and Pharmalectin India: Manage intellectual property and clinical trials, especially in India. (0% of revenue)

Growth Spurts and Science Sprints: Expansion Moves

• Formed Pharmalectin India to run clinical trials locally (2022).
• Recruitment for the Phase 1b/2a trial for ProLectin-M in India was completed in May 2025.
• Received FDA approval for U.S. clinical trial of ProLectin-M (August 2023).
• Plans to schedule a Phase 3 trial for ProLectin-M in 2025, contingent on positive previous trial results, and expects new trials for other drug candidates (2025).
• Raised funds through affiliate loans and planned private placement (2025).

What Makes Bioxytran Stand Out (Without the Lab Coat)

Bioxytran focuses on drugs for low-oxygen conditions, using unique delivery methods and protein-blocking compounds. Its structure relies on subsidiaries to manage research, manufacturing, and intellectual property. The company operates globally, with clinical trials in both the U.S. and India.

Five Things You Need to Know

• No revenue reported for Q2 2025 or prior periods; all products are pre-commercial.
• Net loss was $1.3 million for the six months ended June 30, 2025.
• Research and development spending increased from $27,000 in the first half of 2024 to $452,000 in the first half of 2025.
• Cash on hand was $3,144 as of June 30, 2025, with a $2.8 million working capital deficit.
• Company relies on external funding and faces significant going concern risks.

Bottom Line

Bioxytran remains a research-focused company with no commercial products and ongoing funding needs. Its future depends on clinical trial outcomes and successful capital raising.